Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light-Based therapy may tame kidney transplant rejection

NCT ID NCT07663669

Disease control Sponsor: Centre Hospitalier Universitaire de Besancon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This study looks at whether a treatment called extracorporeal photopheresis can help kidney transplant recipients whose bodies are rejecting the new organ. The treatment involves filtering the patient's blood, treating it with a light-activated drug, and returning it to the body. Researchers will track kidney function over one year to see if the therapy stabilizes or slows the decline in kidney health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
extracorporeal photopheresis
What this could lead to
If effective, this approach could offer a way to control antibody-mediated rejection in kidney transplant patients without increasing immunosuppression.
What could go wrong
This is a small, observational study with no control group, so results may not prove cause and effect. The treatment may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 31 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Kidney transplant recipients presenting with antibody-mediated rejection and treated with extracorporeal photopheresis

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Kidney transplant recipients followed at the University Hospitals of Besançon and Lille between September 1, 2016, and August 31, 2023 * Patients with antibody-mediated rejection (as confirmed by histological analysis of the renal biopsy) * Rejection treated with extracorporeal photopheresis * Subjects who do not object to the use of their personal data and/or biological samples * Subjects affiliated with, or beneficiaries of, the French social security system Exclusion Criteria: * Patients with acute rejection * Pregnant women, women in labor, or breastfeeding mothers * Individuals deprived of liberty by judicial or administrative decision; individuals receiving compulsory psychiatric care; or individuals admitted to a healthcare or social institution for reasons other than research participation * Minors * Adults under legal protection or unable to provide informed consent * Subjects without health insurance coverage * Subjects currently within an exclusion period from another study, or as listed in the "national volunteer registry"

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antibody-mediated rejection in kidney transplant are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute transplant rejection transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antibody-mediated rejection in kidney transplant

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de Besançon

    RECRUITING

    Besançon, 25000, France